Visalytics
Visalytics
approved EB-2 (NIW)

Senior Lecturer

Drug Delivery · Syria · 2023-02-01

Processing Time
173 days
Decision Date
2023-02-01
Location
Malaysia
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop new oral insulin delivery materials and drug delivery carriers using a one-step reproducible process. This work aims to develop DNA and RNA vaccines to treat cancer and other diseases, specifically focusing on nanoparticle-based systems that preserve insulin through stomach acid.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses major public health concerns like diabetes and cancer, offering broad implications for U.S. healthcare and treatment costs.

2 Well-positioned to Advance the Endeavor Met

The petitioner's 8 years of experience, Ph.D., and record of 14 publications with 105 citations demonstrate his capability to lead this research.

3 Balance of Factors Met

The national value of developing effective oral insulin and cancer vaccines outweighs the need for a labor certification.

Why This Petition Was Approved

The case was approved based on the petitioner's Ph.D. in pharmaceuticals, 14 peer-reviewed journal articles, and 3 book chapters which garnered 105 citations. Additionally, the petitioner completed 9 peer reviews and submitted 4 expert recommendation letters confirming the national value of his oral insulin delivery systems.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Dependent
Judging Experience
Original Contributions

Similar Cases

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
Massachusetts 13 days 2021-12-20
The petitioner proposes to develop safe and effective drug delivery platforms, including lipid-based nanoparticles, extracellular vesicles, oral biotherapeutics, and hydrogels. This work utilizes techniques such as microfluidics and high-performance liquid chromatography to facilitate improved targeting and dosage for treating rheumatoid arthritis, diabetes, and cancer.
View Case

Assistant Professor

Pharmaceuticals · Syria

WeGreened EB-2 (NIW) approved
65 days 2022-03-23
The petitioner proposes to continue research in the development of new drug delivery carriers based on nanotechnology using a one-step reproducible process. This work focuses on developing DNA and RNA vaccines and treating diseases such as cancer, Alzheimer's, and diabetes. Additionally, the endeavor includes the development of new pediatric drugs designed to mask unpleasant tastes to ease ingestion for children.
View Case

Scientist

Biotechnology · China

WeGreened EB-2 (NIW) approved
Massachusetts 37 days 2025-07-07
The petitioner proposes to develop efficient, biocompatible lipid nanoparticles (LNPs) to serve as vehicles for delivering gene-based therapeutics and anticancer drugs. Her work focuses on optimizing mRNA-based vaccines, co-delivered chemotherapies, and non-invasive anesthetics to enhance targeting and minimize toxicity. She intends to continue leading LNP development for oral and ocular drug delivery systems within the pharmaceutical industry.
View Case

Postdoctoral Researcher

Nanotechnology · Jordan

WeGreened EB-2 (NIW) approved
Maryland 90 days 2023-05-13
The petitioner proposes to improve the delivery of mRNA therapeutics to increase the effectiveness of gene therapies for incurable conditions. His work focuses on formulating and characterizing novel nanoparticles and developing advanced animal models to test therapeutics for brain diseases like Alzheimer's and anti-cancer drug delivery.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Syria

Case data sourced from publicly available petition decisions and case studies. Decision date: 2023-02-01.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 173 days
Criteria Met 3 / 3
Evidence Types 5

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Syria All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist